Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Melanoma Management|November 22, 2018
Combatting mucosal melanoma: recent advances and future perspectivesHelen Tyrrell, Miranda PayneAdvances in Therapy|March 29, 2021
An Open-Label Tolerability and Actual-Use Human Factors Study of Etrolizumab Autoinjector in Healthy VolunteersHelen Tyrrell, Renato Ravanello, Jennifer Pulley, et al.Advances in Therapy|May 24, 2020
Etrolizumab for the Treatment of Ulcerative Colitis and Crohn's Disease: An Overview of the Phase 3 Clinical ProgramWilliam J Sandborn, Severine Vermeire, Helen Tyrrell, et al.Advances in Therapy|March 29, 2021
Comparable Pharmacokinetics, Safety, and Tolerability of Etrolizumab Administered by Prefilled Syringe or Autoinjector in a Randomized Trial in Healthy VolunteersWenhui Zhang, Helen Tyrrell, Han Ting Ding, et al.Rheumatology (Oxford, England)|September 20, 2011
Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysisPaul Emery, Philip J Mease, Andrea Rubbert-Roth, et al.The Journal of Rheumatology|October 3, 2012
Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX studyEdward C Keystone, Stanley B Cohen, Paul Emery, et al.Journal of Materials Chemistry. A|August 4, 2025
Impact of N-heterocyclic amine modulators on the structure and thermal conversion of a zeolitic imidazole frameworkJavier Castells-Gil, Jinjie Zhu, Ioanna Itskou, et al.Clinical Sarcoma Research|August 18, 2018
Retrospective audit of 957 consecutive 18F-FDG PET-CT scans compared to CT and MRI in 493 patients with different histological subtypes of bone and soft tissue sarcomaRuth E Macpherson, Sarah Pratap, Helen Tyrrell, et al.The Lancet. Gastroenterology & Hepatology|November 19, 2021
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 studySeverine Vermeire, Peter L Lakatos, Timothy Ritter, et al.The Lancet. Gastroenterology & Hepatology|November 19, 2021
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 studySilvio Danese, Jean-Frederic Colombel, Milan Lukas, et al.Pageof 2